Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BG-75202

Small molecule · Inhibitor of lysine acetyltransferase 6A (KAT6A) and lysine acetyltransferase 6B (KAT6B) · developed by BeOne Medicines

Phase 1 Most advanced trial
ONC Developer

What is BG-75202?

BG-75202 is an orally bioavailable inhibitor of the histone acetyltransferases KAT6A (MOZ) and KAT6B (MORF), which binds these enzymes and inhibits acetylation of histones and other nonhistone substrates. It is studied in breast cancer and advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
lysine acetyltransferase 6A (KAT6A), lysine acetyltransferase 6B (KAT6B)
Mechanism
Inhibitor of lysine acetyltransferase 6A (KAT6A) and lysine acetyltransferase 6B (KAT6B)
Pathways
histone acetylation, gene expression regulation, cell cycle regulation
Therapy area
Oncology
Developer
BeOne Medicines (ONC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced Solid TumorBreast Cancer

Other drugs acting on KAT6A / KAT6B

More from BeOne Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.

Follow ONC, the company behind BG-75202

See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ONC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.